Myriad Genetics Management
Management Kriterienprüfungen 1/4
Myriad Genetics CEO ist Sam Raha , ernannt in Apr 2025, hat eine Amtszeit von 1.08 Jahren. Die jährliche Gesamtvergütung beträgt $5.69M , bestehend aus 15.1% Gehalt und 84.9% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.17% der Aktien des Unternehmens, im Wert von $633.34K . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 1.7 Jahre bzw. 5.8 Jahre.
Wichtige Informationen
Sam Raha
Geschäftsführender
US$5.7m
Gesamtvergütung
| Prozentsatz des Geschäftsführergehalts | 15.07% |
| Amtszeit als Geschäftsführer | 1.1yrs |
| Eigentum des Geschäftsführers | 0.2% |
| Durchschnittliche Amtszeit des Managements | 1.7yrs |
| Durchschnittliche Amtszeit der Vorstandsmitglieder | 5.8yrs |
Jüngste Management Updates
Recent updates
Narrativ-Update • Apr 21
MYGN: 2026 Turnaround And Pipeline Milestones Will Keep Sentiment Cautious
Analyst price targets on Myriad Genetics have moved slightly lower, with recent cuts to $6 from $8 and $6.50, as analysts wait for clearer evidence of progress on the turnaround plan, pipeline milestones, and improved growth and profitability before shifting their stance. Analyst Commentary Recent Street research reflects a cautious stance on Myriad Genetics, with bearish analysts trimming price targets and highlighting execution and growth risks despite some operational positives.Narrativ-Update • Apr 05
MYGN: 2026 Turnaround Execution And Pipeline Delivery Will Sustain Bearish Caution
Analysts have trimmed their price targets on Myriad Genetics to a range of $6 to $7, reflecting caution around the pace of the turnaround and the need for clearer progress on growth, profitability and pipeline execution before taking a more constructive stance. Analyst Commentary Recent research updates point to a cautious tone, with several bearish analysts trimming price targets into the US$6 to US$7 range and maintaining neutral ratings.Seeking Alpha • Mar 31
Myriad Genetics: SOTP Suggests The Company Is Undervalued
Summary Myriad Genetics, Inc. has grown from a mainly Hereditary Cancer business into a broader precision medicine company, but the market still values it at a low multiple because earnings, cash flow, and. The strongest part of the business is still the core Hereditary Cancer franchise, which has shown better resilience than other units through stronger volume trends and steadier operating performance. Even on a conservative sum-of-the-parts basis, the stock appears undervalued, with an estimated value of about $6.05 per share versus the current market price. Followed by portfolio simplification can bring further upside. Near-term catalysts in 2026, including HCT Precise MRD customer testing, the planned AI-enabled Prolaris launch, and continued cost discipline, could help narrow the valuation gap. Read the full article on Seeking AlphaNarrativ-Update • Mar 21
MYGN: Turnaround Execution In 2026 Will Drive Continued Cautious Sentiment
The Street’s blended price target for Myriad Genetics has shifted lower into a $6 to $7 range as analysts factor in updated sector models, reiterated 2026 guidance, and the need for clearer progress on the company’s turnaround and profitability before becoming more constructive. Analyst Commentary Recent research updates show a clear tilt toward caution, with several bearish analysts trimming their valuation ranges for Myriad Genetics and keeping ratings in the middle of the scale rather than moving to a more positive stance.Narrativ-Update • Mar 06
MYGN: Turnaround Execution And 2026 Pipeline Milestones Will Drive Bearish Outlook
Analysts have trimmed their price targets on Myriad Genetics to a range of about $6 to $7, reflecting more cautious assumptions on growth and profitability even as they acknowledge recent results and the company’s ongoing turnaround efforts. Analyst Commentary Recent research updates show bearish analysts trimming price targets on Myriad Genetics into a tighter band around $6 to $7, signaling a more cautious stance on the stock even as they acknowledge operational progress.Narrativ-Update • Feb 19
MYGN: Rebased Outlook Weighs Execution Risks Against Upcoming MRD Commercialization Potential
Analysts have adjusted their outlook on Myriad Genetics, trimming the average price target to $7 from $9. They have also updated their assumptions around fair value, discount rate, revenue growth, profit margins, and future P/E based on recent diagnostics sector research and expectations for solid results and 2026 guidance.Analyseartikel • Feb 13
Little Excitement Around Myriad Genetics, Inc.'s (NASDAQ:MYGN) Revenues As Shares Take 27% Pounding
To the annoyance of some shareholders, Myriad Genetics, Inc. ( NASDAQ:MYGN ) shares are down a considerable 27% in the...
Narrativ-Update • Feb 05
MYGN: Sector Fundamentals And New Diagnostics Partnerships Will Support A More Constructive Outlook
Analysts have lowered their price target on Myriad Genetics to $7 from $9, reflecting updated assumptions on fair value, discount rate, revenue growth, profit margin and future P/E, while still expecting solid diagnostics sector results and 2026 outlooks. Analyst Commentary Recent research on Myriad Genetics focuses on how the updated $7 price target lines up with expectations for the broader diagnostics group, where analysts still see solid sector results and 2026 outlooks supported by what they describe as strong fundamentals.Analyseartikel • Feb 04
Does Myriad Genetics (NASDAQ:MYGN) Have A Healthy Balance Sheet?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Narrativ-Update • Jan 22
MYGN: Sector Strength And Expanded Cancer Testing Will Support Future Upside
Narrative Update Analysts have adjusted their view on Myriad Genetics, reflected in a higher fair value estimate from $14.33 to $16.06 as they weigh mixed price target moves in recent research and slightly different assumptions for growth, margins, and future P/E. Analyst Commentary Recent Street research on Myriad Genetics presents a mixed but informative picture, with some caution on price targets alongside more constructive adjustments that support the updated fair value estimate.Narrativ-Update • Jan 08
MYGN: Sector Strength And New Partnerships Will Support A More Constructive Outlook
Narrative Update The analyst price target for Myriad Genetics has shifted modestly lower, with a blended change of roughly $1 across recent moves to $7 and $8. Analysts are factoring in updated diagnostics sector expectations and revising their fair value estimates and P/E outlooks for the company.Narrativ-Update • Dec 24
MYGN: Rising Margin Visibility Will Support A More Constructive Bullish Outlook
Analysts have raised their price target on Myriad Genetics shares from $6.00 to $8.00, reflecting modest improvements in long term profit margin expectations and valuation assumptions, while maintaining a neutral overall outlook. Analyst Commentary Analyst commentary around the revised price target highlights a generally balanced view, with recognition of incremental progress offset by lingering execution and profitability concerns.Narrativ-Update • Dec 10
MYGN: Improved Earnings Visibility Will Shape Bullish Outlook
Analysts have modestly raised their price target on Myriad Genetics to $8 from $6, reflecting a slightly higher fair value estimate supported by improved forward price to earnings assumptions and a marginally higher discount rate that still preserves cautious revenue growth expectations. Analyst Commentary Analyst sentiment around Myriad Genetics remains balanced, with the higher price target reflecting modest improvements in forward expectations rather than a decisive shift in outlook.Narrativ-Update • Nov 26
MYGN: Breast Cancer Risk Collaboration And Margin Gains Will Shape Outlook
Narrative Update on Myriad Genetics Analysts have raised their price target for Myriad Genetics from $6 to $8, citing improved profit margins and modest revenue growth as key drivers for the upward revision. Analyst Commentary Analyst opinions about Myriad Genetics reflect a mix of optimism regarding the company's recent performance and continued caution around potential challenges.Narrativ-Update • Nov 12
MYGN: Expanded Cancer Testing Is Expected To Drive Future Gains
Narrative Update on Myriad Genetics Analysts have increased their price target for Myriad Genetics from $6 to $8. This adjustment reflects revised expectations based on updates to fair value assessments, discount rates, and future earnings metrics.Narrativ-Update • Oct 29
Adding Cancer Test Capabilities And Mental Health Data Will Support Long-Term Progress
Analysts have slightly raised their price target for Myriad Genetics to approximately $7.95 from $7.77 per share. They cited modest improvements in expected profit margins and updated assumptions around discount rates.Narrativ-Update • Oct 14
Expanding Oncology Testing And Genomic Profiling Will Widen Market Reach
Analysts have adjusted their price target for Myriad Genetics upward from $7.38 to $7.77, citing minor improvements in profit margin and future price-to-earnings expectations, even though revenue growth projections have been slightly reduced. What's in the News Myriad Genetics has formed a strategic partnership with SOPHiA GENETICS to develop and globally deploy a liquid biopsy companion diagnostic test for pharmaceutical companies, leveraging both companies' expertise and international networks (Strategic Alliances).Analyseartikel • Sep 30
Estimating The Intrinsic Value Of Myriad Genetics, Inc. (NASDAQ:MYGN)
Key Insights Myriad Genetics' estimated fair value is US$8.13 based on 2 Stage Free Cash Flow to Equity Myriad...Analyseartikel • Aug 17
Myriad Genetics, Inc. (NASDAQ:MYGN) Held Back By Insufficient Growth Even After Shares Climb 28%
NasdaqGS:MYGN 1 Year Share Price vs Fair Value Explore Myriad Genetics's Fair Values from the Community and select...Analyseartikel • Jun 25
Myriad Genetics, Inc. (NASDAQ:MYGN) Stock Catapults 29% Though Its Price And Business Still Lag The Industry
Those holding Myriad Genetics, Inc. ( NASDAQ:MYGN ) shares would be relieved that the share price has rebounded 29% in...Analyseartikel • May 09
Lacklustre Performance Is Driving Myriad Genetics, Inc.'s (NASDAQ:MYGN) 48% Price Drop
To the annoyance of some shareholders, Myriad Genetics, Inc. ( NASDAQ:MYGN ) shares are down a considerable 48% in the...
Neues Narrativ • Mar 24
PATHOMIQ AI Partnership Will Expand Oncology And Women's Health
Strategic partnerships and investments in AI and women's health aim to enhance oncology offerings and capture larger market shares, driving revenue growth.Analyseartikel • Mar 16
Myriad Genetics, Inc. (NASDAQ:MYGN) Not Doing Enough For Some Investors As Its Shares Slump 31%
Myriad Genetics, Inc. ( NASDAQ:MYGN ) shareholders that were waiting for something to happen have been dealt a blow...Analyseartikel • Feb 26
Here's What Analysts Are Forecasting For Myriad Genetics, Inc. (NASDAQ:MYGN) After Its Yearly Results
There's been a notable change in appetite for Myriad Genetics, Inc. ( NASDAQ:MYGN ) shares in the week since its annual...Seeking Alpha • Jan 16
Myriad Genetics: Navigating Through A Setback
Summary Myriad Genetics, Inc.'s stock value has halved recently, despite Q3 results released in early November beating expectations. Management has succeeded in reducing GAAP net losses, but has a new challenge with policy changes from United Healthcare that took effect at the beginning of this year. This has impacted FY2025 initial guidance and cratered the stock over the past nine weeks. Are MYGN shares in the 'buy zone' yet? An analysis of Myriad Genetics follows in the paragraphs below. Read the full article on Seeking AlphaAnalyseartikel • Jan 08
An Intrinsic Calculation For Myriad Genetics, Inc. (NASDAQ:MYGN) Suggests It's 45% Undervalued
Key Insights Using the 2 Stage Free Cash Flow to Equity, Myriad Genetics fair value estimate is US$26.22 Current share...Analyseartikel • Nov 13
Myriad Genetics, Inc. (NASDAQ:MYGN) Just Reported Earnings, And Analysts Cut Their Target Price
Last week, you might have seen that Myriad Genetics, Inc. ( NASDAQ:MYGN ) released its quarterly result to the market...Analyse der Geschäftsführervergütung
| Datum | Gesamtvergütung | Gehalt | Unternehmensgewinne |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$400m |
| Dec 31 2025 | US$6m | US$857k | -US$366m |
| Sep 30 2025 | n/a | n/a | -US$400m |
| Jun 30 2025 | n/a | n/a | -US$395m |
| Mar 31 2025 | n/a | n/a | -US$101m |
| Dec 31 2024 | US$4m | US$750k | -US$127m |
| Sep 30 2024 | n/a | n/a | -US$116m |
| Jun 30 2024 | n/a | n/a | -US$155m |
| Mar 31 2024 | n/a | n/a | -US$235m |
| Dec 31 2023 | US$5m | US$14k | -US$263m |
Vergütung im Vergleich zum Markt: SamDie Gesamtvergütung ($USD5.69M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD2.65M).
Entschädigung vs. Einkommen: SamDie Bezüge der Mitarbeiter sind gestiegen, während das Unternehmen unrentabel ist.
Geschäftsführer
Sam Raha (52 yo)
1.1yrs
Amtszeit
US$5,686,740
Vergütung
Mr. Samraat S. Raha, also known as Sam, served as Chief Operating Officer at Myriad Genetics, Inc. since December 11, 2023 until April 30, 2025 and serves as its President, Chief Executive Officer and Dire...
Führungsteam
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| President | 1.1yrs | US$5.69m | 0.17% $ 633.3k | |
| CFO & Principal Accounting Officer | less than a year | US$1.51m | 0.32% $ 1.2m | |
| Chief Operating Officer | 1.1yrs | US$3.15m | 0.67% $ 2.5m | |
| Chief Scientific Officer | 4.3yrs | US$1.86m | 0.35% $ 1.3m | |
| Consultant | 1.1yrs | US$1.52m | 0.66% $ 2.4m | |
| Chief Commercial Officer | 1yr | US$6.00m | 0.057% $ 211.3k | |
| Senior Vice President of Investor Relations | no data | keine Daten | keine Daten | |
| Chief Legal Officer | 1.7yrs | keine Daten | 0.028% $ 101.9k | |
| Chief People Officer | 3.2yrs | keine Daten | 0.037% $ 136.3k | |
| Executive Vice President of Innovation & Strategic Partnerships | 5yrs | keine Daten | keine Daten | |
| Chief Medical Officer | 6.2yrs | keine Daten | keine Daten | |
| Senior Vice President of Revenue Cycle Management | 5.3yrs | keine Daten | keine Daten |
1.7yrs
Durchschnittliche Betriebszugehörigkeit
52yo
Durchschnittliches Alter
Erfahrenes Management: MYGNDas Führungsteam des Unternehmens gilt nicht als erfahren ( 1.7 Jahre durchschnittliche Betriebszugehörigkeit), was auf ein neues Team schließen lässt.
Vorstandsmitglieder
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| President | 1.1yrs | US$5.69m | 0.17% $ 633.3k | |
| Independent Director | 3.6yrs | US$334.25k | 0.050% $ 186.3k | |
| Independent Director | 6.7yrs | US$343.00k | 0.087% $ 322.0k | |
| Independent Director | 5.8yrs | US$328.50k | 0.091% $ 336.3k | |
| Independent Director | 6.7yrs | US$338.50k | 0.045% $ 166.3k | |
| Independent Director | 15.9yrs | US$338.50k | 0.13% $ 475.6k | |
| Independent Director | 1.4yrs | US$211.93k | keine Daten | |
| Independent Chair of the Board | 16.7yrs | US$451.00k | 0.28% $ 1.0m | |
| Independent Director | 5.7yrs | US$328.50k | 0.082% $ 302.6k |
5.8yrs
Durchschnittliche Betriebszugehörigkeit
64yo
Durchschnittliches Alter
Erfahrener Vorstand: MYGNDie Vorstandsmitglieder gelten als erfahren (5.8 Jahre durchschnittliche Amtszeit).
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/05/22 04:22 |
| Aktienkurs zum Tagesende | 2026/05/22 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Myriad Genetics, Inc. wird von 37 Analysten beobachtet. 10 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Jack Meehan | Barclays |
| Derek Taller | Benchmark Company |
| Michael Ryskin | BofA Global Research |